The purpose of this study is to assess the impact of ten intravenous infusions of 3 mg/kg CER
001 vs. placebo, given at weekly intervals for ten weeks, on atherosclerotic plaque volume as
measured by coronary IVUS, when administered to subjects presenting with Acute Coronary
Syndrome (ACS) with significant plaque volume.
Phase:
Phase 2
Details
Lead Sponsor:
Cerenis Therapeutics, SA
Collaborator:
South Australian Health and Medical Research Institute